Sydney M Crago

EyeBio has begun the dosing of the first participants in its Phase 1b/2 AMARONE clinical trial for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).

The open source article reports on the anti-inflammatory compound and its potential to treat retinal diseases.

This approval will allow Belite Bio to initiate the phase 3 clinical trial in South Korea, also known as the DRAGON study.

This two-in-one option, PreserVision AREDS 2 Formula eye vitamins plus CoQ10 combines the exact nutrient formula recommended by the National Eye Institute (NEI) to help reduce the risk of moderate to advanced Age-related Macular Degeneration (AMD) progression.

The 12-month data demonstrated maintenance of controlled wet AMD subjects comparable to aflibercept injections every eight weeks with a single administration of OTX-TKI.

The company’s pipeline includes treatments for XLRP, AMD, and cone-rod dystrophy (CRD).

OTX-TKI is the Ocular Therapeutix’s axitinib intravitreal implant that is being developed for the treatment of diabetic retinopathy, wet AMD and other retinal diseases.

Ocular Therapeutix is scheduled to present trial results as well as participate in a panel discussion and sponsor a presentation at the 2023 Clinical Trials at the Summit Annual Meeting.

PAVIA is a 12-month, randomized, controlled phase 2 clinical trial of EYP-1901 in patients with moderate to severe NPDR.

This funding will allow for the registration and launch of gilderuretinol, the first and only medicine in clinical development to address the underlying mechanism of Stargardt disease.

Intelligent Retinal Imaging Systems (IRIS) celebrates the company’s 1 millionth diabetic retinal exam.

Aviceda Therapeutics doses its first patient with AVD-104 in its Phase 2 SIGLEC Trial. This intravitreal asset is being tried for treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

VABYSMO is the first treatment for wet AMD and DME in Canada that acts by targeting both VEGF-A and Ang-2, two key drivers of vascular instability that have been associated with vision-threatening retinal conditions.

The company is currently developing treatments for age related macular degeneration as injections and eye drops, among others.

Data supports ANX007 as the first complement therapy to preserve visual acuity, achieving statistically significant protection, but reduction in rate of geographic atrophy lesion growth did not reach statistical significance.

Allgenesis announces preliminary data for its on-going trial and anticipates the release of the final topline data in 4Q23.

The iPredictTM AI Eye Screening System will provide a fully automated age-related macular degeneration (AMD) screening report in less than 60 seconds.

PMC-403 is a first-in-class antibody that activates TIE2, a receptor specifically expressed in vascular endothelial cells. The clinical trial will take place in multiple hospitals in South Korea.

The research conducted at the Wayne State University School of Medicine implies that VCAM1 antagonism could be a promising therapeutic strategy for proliferative retinal disorders.

Data presented at the ASGCT 2023 Annual Meeting supports that Adverum’s Ixo-vec allows for lower dose administration with improved inflammation profile.

Early clinical studies indicate that Vitargus® has unique properties that could eliminate the need for patients to remain face-down after retinal detachment and vitreous hemorrhage surgery.

The company made these announcements at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting in Los Angeles, California.

The sale of YUTIQ® will empower EyePoint Pharmaceuticals to continue to advance its pipeline of therapeutics through the company's upcoming clinical trials.

The company received $100 million (USD) in this financing round from several investment partners as they generate new optogenetic therapeutics for blinding diseases.

Researchers at the Medical College of Georgia have shown in an animal model of retinopathy of prematurity that the small molecule K604 can block the development of leaky, obstructive blood vessels in the retina, tamp down inflammation and enable more normal blood vessel growth.

Aviceda Therapeutics appoints Patrick Johnson, a strategic pharmaceutical executive, to its board of directors.

Eyetelligence will offer non-invasive point-of-care technology to diagnose a range of diseases, including diabetic retinopathy and age-related macular degeneration, with AI algorithmic retinal image analysis.

A study by Verana Health shows how de-identified real-world data (RWD) from electronic health records (EHRs) in medical registries can allow for a deeper understanding of data trends, patterns, or gaps.

This medical device is the first retinal eye-movement monitor for non-invasive, objective clinical assessments.

The study results show the potential of SREDs to treat progressive, chronic retina conditions including age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinitis pigmentosa (RP).